CRI Awards $10 Million to Advance Immune-Based Cancer Treatments Cancer Research Institute, Inc. (CRI) announced that it has committed more than $10 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development at research centers worldwide. [Cancer Research Institute] Press Release Temple Researchers Receive $11.6 Million to Study Ways to Reduce Heart Attack Damage Researchers have been awarded a five-year, $11.6 million grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to develop new approaches to prevent, slow, or reverse damage to the heart after a heart attack. [Temple University School of Medicine] Press Release NeoStem Reports Data Safety Monitoring Board Recommends Continuation of PreSERVE AMI Phase II Trial Amorcyte, a company of NeoStem, Inc., announced that it received approval to continue its PreSERVE AMI Phase II clinical trial following its first interim data and safety review by the Data Safety Monitoring Board. The trial’s product candidate, AMR-001, is designed to prevent major adverse cardiac events following acute myocardial infarction (AMI). [NeoStem, Inc.] Press Release New Pancreatic Cancer Clinical Trial Applies Revolutionary Immunotherapy Approach That Genetically Modifies T Cells The Lustgarten Foundation and the Cancer Research Institute are co-sponsoring a new approach to the treatment of pancreatic cancer. A new clinical trial led by Dr. Carl June and Dr. Gregory Beatty at the Perelman School of Medicine at the University of Pennsylvania will focus on altering and training a patient’s immune system to target and eliminate cancer cells. [Cancer Research Institute] Press Release ACT Announces Scotland’s NHS Lothian as Additional Site for EU Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration Advanced Cell Technology, Inc. (ACT) announced that Scotland’s NHS Lothian has been confirmed as a site for its Phase I/II human clinical trial for Stargardt’s Macular Dystrophy using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). [Advanced Cell Technology, Inc.] Press Release Pluristem Receives Approval from Indian Ministry of Health for Use of PLX Cells in Phase II Trial for Treatment of Buerger’s Disease Pluristem Therapeutics, Inc. announced that it has received permission from the Indian Ministry of Health to proceed with a Phase II clinical trial for the treatment of thromboangiitis obliterans (Buerger’s disease). This Phase II trial will be potentially followed by a larger multi-national Phase III study in the U.S., Europe and India. [Pluristem Therapeutics, Inc.] Press Release Oxford BioMedica Announces Positive DSMB Review of Ongoing RetinoStat® and StarGen™ Clinical Studies Oxford BioMedica plc and its partner Sanofi announced a positive interim review of the RetinoStat® Phase I study in neovascular “wet” age-related macular degeneration and the StarGen™ Phase I/IIa study in Stargardt disease by the Data Safety Monitoring Board (DSMB). RetinoStat® and StarGen™ were designed and developed by Oxford BioMedica using the Company’s proprietary LentiVector® gene delivery technology. [Oxford BioMedica plc] Press Release Northwest Bio Expands Worldwide Production Capacity for DCVax®-L Northwest Biotherapeutics announced that it is entering into amended agreements to double the production capacity in the U.S. for the manufacture of the Company’s DCVax®-L immune therapy for Glioblastoma multiforme patients. [Northwest Biotherapeutics, Inc.] Press Release |